145 related articles for article (PubMed ID: 11007964)
1. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors.
Liu A; Prendergast GC
FEBS Lett; 2000 Sep; 481(3):205-8. PubMed ID: 11007964
[TBL] [Abstract][Full Text] [Related]
2. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
Du W; Prendergast GC
Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
[TBL] [Abstract][Full Text] [Related]
3. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Du W; Lebowitz PF; Prendergast GC
Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
[TBL] [Abstract][Full Text] [Related]
4. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
Liu Ax; Du W; Liu JP; Jessell TM; Prendergast GC
Mol Cell Biol; 2000 Aug; 20(16):6105-13. PubMed ID: 10913192
[TBL] [Abstract][Full Text] [Related]
5. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
Zeng PY; Rane N; Du W; Chintapalli J; Prendergast GC
Oncogene; 2003 Feb; 22(8):1124-34. PubMed ID: 12606940
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB.
Lebowitz PF; Casey PJ; Prendergast GC; Thissen JA
J Biol Chem; 1997 Jun; 272(25):15591-4. PubMed ID: 9188444
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase.
Wherlock M; Gampel A; Futter C; Mellor H
J Cell Sci; 2004 Jul; 117(Pt 15):3221-31. PubMed ID: 15226397
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.
Prendergast GC
Histol Histopathol; 2001 Jan; 16(1):269-75. PubMed ID: 11193202
[TBL] [Abstract][Full Text] [Related]
10. RhoB and the cellular response to farnesyltransferase inhibitors: the search for clues to cell death mechanisms.
Bernhard EJ
Cancer Biol Ther; 2003; 2(3):281-2. PubMed ID: 12878866
[No Abstract] [Full Text] [Related]
11. Actin' up: RhoB in cancer and apoptosis.
Prendergast GC
Nat Rev Cancer; 2001 Nov; 1(2):162-8. PubMed ID: 11905808
[TBL] [Abstract][Full Text] [Related]
12. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB.
Kamasani U; Liu AX; Prendergast GC
Cancer Biol Ther; 2003; 2(3):273-80. PubMed ID: 12878865
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects.
Prendergast GC
Curr Opin Cell Biol; 2000 Apr; 12(2):166-73. PubMed ID: 10712917
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells.
Pan J; She M; Xu ZX; Sun L; Yeung SC
Cancer Res; 2005 May; 65(9):3671-81. PubMed ID: 15867362
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
Delarue FL; Adnane J; Joshi B; Blaskovich MA; Wang DA; Hawker J; Bizouarn F; Ohkanda J; Zhu K; Hamilton AD; Chellappan S; Sebti SM
Oncogene; 2007 Feb; 26(5):633-40. PubMed ID: 16909123
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR
Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869
[TBL] [Abstract][Full Text] [Related]
17. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells.
Mazières J; Tillement V; Allal C; Clanet C; Bobin L; Chen Z; Sebti SM; Favre G; Pradines A
Exp Cell Res; 2005 Apr; 304(2):354-64. PubMed ID: 15748883
[TBL] [Abstract][Full Text] [Related]
18. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
Oncogene; ; . PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
